Rivaroxaban in atrial fibrillation

15th June 2012 by Louise Hudman

This guideline is for Rivaroxaban, which is a Factor Xa inhibitor and has been approved for use in patients with nonvalvular AF and at least one of the following risk factors (which equates to a CHADS2 score of at least 1):

  • CHF
  • Hypertension
  • 75 or older
  • Diabetes
  • CVA or TIA

It is very expensive, but it’s main bonus is that no monitoring is needed. It has a similar safety profile to warfarin (it seems to cause more GI bleeds, but fewer intracranial bleeds – though only in those who’ve previously had warfarin). It is not inferior in effectiveness to warfarin. The study wasn’t good enough to compare it to dagabatrin.

The advice from NICE is to discuss the pros and cons with the patient. Those most likely to benefit are those whose INR is not well controlled. The trial didn’t show much for people with CHADS2 score of 1, so they may get less benefit.

Read more

No bank details needed.

Join free trial

Login

Already a member? Login to view this content.

Login

"LocumDeck does everything you want it to do in an instant and with audit trails.

I absolutely love the facility for receiving Locum's invoices and the facility for signing the Pension Forms electronically and they are then instantly sent with an audit trail! It is fabulous!

You are notified the moment a Locum GP adds availability which is just fantastic, I spend a lot of time just chasing agencies to see if they have availability, so to be notified the moment availability is advertised is a new concept and very welcome! I have no hesitation in recommending LocumDeck - it has already eased my workload!"

Sue, Practice Manager in Portsmouth

See the full list of features within our NASGP membership plans

Membership